/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Wireless Telecom Group Announces First Quarter 2019 Financial Results
Highlights for the quarter ended March 31, 2019:
-
Net revenues of $13,032,000, reflecting growth in two of three
segments - Gross Profit of $5,727,000, or 43.9%
- Net loss of $344,000
- Non-GAAP Adjusted EBITDA of $354,000
- New Customer orders of $12,387,000
- March 31, 2019 backlog of firm orders of $7,575,000
- Decrease in S,G&A, increase in R&D to drive future growth
-
Company announces target revenues of $100 million by 2023,
inclusive of acquisitions
PARSIPPANY, N.J.–(BUSINESS WIRE)–Wireless Telecom Group, Inc. (NYSE American: WTT) (the “Company”)
announced today results for the 2019 first quarter ended March 31, 2019.
Tim Whelan, CEO of Wireless Telecom Group, Inc., commented, “Our Q1
financial results were as we expected exiting 2018 which was a record
year for the Company. Revenue was comparable to last year’s Q1 and
yielded margins reflecting our revenue product mix of lower software and
more hardware cards. We are pleased with continued top-line strength in
Embedded Solutions and the year over year increase in Network
Solutions.” Whelan added, “We are excited about our R&D investments and
the product initiatives we released during the first quarter across
multiple segments which included product collaboration on LTE eNodeB
software, our product launch for real-time public safety monitoring, and
our launch of noise sources for 5G test systems.”
Whelan continued, “We continue to invest for long-term growth and remain
optimistic for continued momentum throughout the remainder of 2019. We
are on track for our long-term target of $100 million in revenue,
consisting of strong organic growth and strategic acquisitions, while
improving profitability and cash flows.”
For the quarter ended March 31, 2019, the Company reported consolidated
net revenues of $13,032,000, compared to $13,264,000 for the same period
in 2018, a decrease of 1.7%. Network Solutions revenue increased 4.5% on
increased large venue projects and customized solutions and Embedded
Solutions revenue increased 6.4% on higher sales of digital signal
processing hardware. This was offset by a decrease of 19.5% in Test and
Measurement revenue on lower government shipments compared to the same
quarter last year, which are expected to increase over the coming
quarters.
The Company also reported consolidated gross profit of $5,727,000, or
43.9% of revenue, for the quarter ended March 31, 2019, compared to
$6,268,000 or 47.3% of revenue, for the same period in 2018. The decline
in gross profit margin was due to a higher mix of lower margin hardware
sales at Embedded Solutions and the impact of competitive pricing in the
Network Solutions industry which were partially offset due to a
favorable product mix in Test and Measurement.
For the quarter ended March 31, 2019, the Company reported consolidated
operating expenses of $6,125,000, compared to $5,700,000 for the same
period in 2018, an increase of $425,000. The increase was driven by our
investments in research and development in the area of 5G roadmap
development and was offset by a 3% decline of sales, marketing, general
and administrative expenses.
The net loss for the quarter ended March 31, 2019 was $344,000, compared
to net income of $374,000 for the same period in 2018.
Non-GAAP Adjusted EBITDA for the quarter ended March 31, 2019 was
$354,000, compared to $1,612,000 for the same period in 2018. The
decrease in non-GAAP Adjusted EBITDA from the prior year is attributable
to the decrease in gross profit as described above coupled with the
increased investments in research and development. The Company’s
explanation of Adjusted EBITDA and the reconciliation of Adjusted EBITDA
to net income (loss) is set out below in this press release.
The Company’s consolidated backlog of firm orders to be shipped in the
next twelve months was $7,575,000 at March 31, 2019, compared to the
March 31, 2018 backlog of $10,576,000.
Outlook
Near term, the Company expects revenues for the second quarter of 2019
to slightly increase compared to the same quarter last year and gross
margins to be comparable. The Company also maintains the expectation for
full year 2019 revenues to grow organically in the low to mid-single
digits, with full-year gross margins comparable to last year. A strict
focus on driving operational leverage is expected to generate
profitability and cash flow growth at rates higher than expected revenue
growth. The Company’s principal considerations for full-year 2019
expectations include slower than anticipated deployment of 5G
infrastructure, judicious investment in R&D and new product development
while controlling operating expenses, and uncertainty around the timing
of select, large and new customer opportunities in the funnel.
Beyond 2019, the Company expects to grow revenues organically between 10
and 12% over the next four years based on the long term trends of
network densification and 5G deployment, private LTE network expansion
and increased military spend. In addition, the Company also expects
strong organic growth to be driven by multiple internal initiatives
including the continuation of new product introductions, channel
expansion, and operational excellence. The Company’s 2023 targets also
include annual revenues of $100 million, inclusive of strategic
acquisitions, gross profit margins between 47% and 49%, and Adjusted
EBITDA margins of approximately 15%. The Company defines Adjusted EBITDA
margins as Adjusted EBITDA divided by revenue (see use of Non-GAAP
Financial Measures below).
Conference Call
As previously announced, Wireless Telecom Group Inc. will host a
conference call today at 8:30 a.m. ET in which management will discuss
first quarter results and related matters. To participate in the
conference call, dial 800-346-7359 or 973-528-0008. The conference
identification number is 762201. The call will also be webcast over the
internet at the following URL: https://www.webcaster4.com/Webcast/Page/1690/30414
A replay will be made available on the Wireless Telecom website for a
limited period of time following the conference call.
Use of Non-GAAP Financial Measures
The Company reports its financial results in accordance with generally
accepted accounting principles (“GAAP”). Management believes, however,
that certain non‐GAAP financial measures used in managing the Company’s
business may provide users of this financial information with additional
meaningful comparisons between current results and prior reported
results. Certain of the information set forth herein and certain of the
information presented by the Company from time to time may constitute
non‐GAAP financial measures within the meaning of Regulation G adopted
by the Securities and Exchange Commission. We have presented herein a
reconciliation of these measures to the most directly comparable GAAP
financial measure. The non‐GAAP measures presented herein may not be
comparable to similarly titled measures presented by other companies.
The foregoing measures do not serve as a substitute and should not be
construed as a substitute for GAAP performance, but provide supplemental
information concerning our performance that our investors and we find
useful.
The Company defines EBITDA as its net earnings before interest, taxes,
depreciation and amortization. “Adjusted EBITDA” is EBITDA excluding our
stock compensation expense, restructuring charges, acquisition expenses,
integration expenses, the one-time non-cash inventory impairment
charges, unrealized and realized foreign exchange gains and losses, and
other non-recurring costs and includes cash received in 2018 related to
revenue that would have been recognized in 2018 but for the adoption of
ASU Topic 606. A reconciliation of net income to non-GAAP Adjusted
EBITDA is included as an attachment to this press release.
The Company defines Adjusted EBITDA margin as Adjusted EBITDA divided by
revenue. The Company does not provide a forward-looking reconciliation
of expected Adjusted EBITDA Margin as the amount and significance of
special items required to develop meaningful comparable GAAP financial
measures cannot be estimated at this time without unreasonable efforts.
These special items could be meaningful.
The Company views Adjusted EBITDA and Adjusted EBITDA margin as
important indicators of performance, consistent with the manner in which
management measures and forecasts the Company’s performance. We believe
Adjusted EBITDA and Adjusted EBITDA margin are important performance
metrics because they facilitate the analysis of our results, exclusive
of certain non‐cash items, including items which do not directly
correlate to our business operations.
The Company believes that Adjusted EBITDA and Adjusted EBITDA margin
metrics provide qualitative insight into our current performance and we
use these measures to evaluate our results. Additionally, we use
Adjusted EBITDA to measure the performance of our management team and
management’s entitlement to incentive compensation. We believe that
making this information available to investors enables them to view our
performance the way that we view our performance and thereby gain a
meaningful understanding of our core operating results, in general, and
from period to period.
Forward-Looking Statements
This press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. In some
cases, such forward-looking statements may be identified by terms such
as believe, expect, seek, may, will, intend, project, anticipate, plan,
estimate, guidance or similar words. Forward-looking statements include,
among others, statements regarding expectations for revenue and gross
margins for the quarter ending June 30, 2019 and the year ending
December 31, 2019, expectations for increased government shipments in
the remaining quarters of 2019; expectations for improved profitability
and cash flow for the year ending December 31, 2019; expectations
relating to long-term growth, including long-term revenue expectations
of$100 million; long-term organic revenue growth rates, gross profit
margins and Adjusted EBITDA margins. Investors are cautioned that such
forward-looking statements are not guarantees of future performance and
involve a number of risks and uncertainties that could materially affect
actual results, including, among others, the ability of management to
successfully implement the Company’s business plan and strategy; the
loss of any significant customers of the Company; the Company’s ability
to acquire accretive businesses and successfully integrate acquired
businesses; product demand and development of competitive technologies
in the Company’s market sector; the impact of competitive products and
pricing; as well as other risks and uncertainties set forth in the
Company’s Annual Report on Form 10-K for the year ended December 31,
2018. These forward-looking statements speak only as of the date of this
release and the Company does not undertake any obligation to update or
revise any forward-looking information to reflect changes in
assumptions, the occurrence of unanticipated events, or otherwise, as
except as required by law.
About Wireless Telecom Group, Inc.
Wireless Telecom Group, Inc., comprised of Boonton Electronics,
CommAgility, Microlab and Noisecom, is a global designer and
manufacturer of advanced radio frequency and microwave components,
modules, systems and instruments. Serving the wireless,
telecommunication, satellite, military, aerospace, semiconductor and
medical industries, Wireless Telecom Group products enable innovation
across a wide range of traditional and emerging wireless technologies.
With a unique set of high-performance products including peak power
meters, signal analyzers, signal processing modules, LTE PHY and stack
software, power splitters and combiners, GPS repeaters, public safety
monitors, noise sources, and programmable noise generators, Wireless
Telecom Group supports the development, testing, and deployment of
wireless technologies around the globe. Wireless Telecom Group is
headquartered in Parsippany, New Jersey, in the New York City
metropolitan area, and maintains a global network of Sales and Service
offices for excellent product service and support. Wireless Telecom
Group’s website address is http://www.wtcom.com.
Wireless Telecom Group Inc. |
|||||||||
Three Months Ended | |||||||||
March 31 | |||||||||
2019 |
2018 |
||||||||
NET REVENUES | $ | 13,032 | $ | 13,264 | |||||
COST OF REVENUES | 7,305 | 6,996 | |||||||
GROSS PROFIT | 5,727 | 6,268 | |||||||
Operating Expenses | |||||||||
Research and Development | 1,714 | 1,157 | |||||||
Sales and Marketing | 1,937 | 1,910 | |||||||
General and Administrative | 2,474 | 2,633 | |||||||
Total Operating Expenses | 6,125 | 5,700 | |||||||
Operating Income/(Loss) | (398 | ) | 568 | ||||||
Other Income/(Expense) | 31 | (46 | ) | ||||||
Interest Expense | (115 | ) | (92 | ) | |||||
Income/(Loss) before taxes | (482 | ) | 430 | ||||||
Tax Provision/(Benefit) | (138 | ) | 56 | ||||||
Net Income/(Loss) | $ | (344 | ) | $ | 374 | ||||
Other Comprehensive Income/(Loss): | |||||||||
Foreign Currency Translation Adjustments | 305 | 579 | |||||||
Comprehensive Income/(Loss) | $ | (39 | ) | $ | 953 | ||||
Earnings/(Loss) Per Share: | |||||||||
Basic | $ | (0.02 | ) | $ | 0.02 | ||||
Diluted | $ | (0.02 | ) | $ | 0.02 | ||||
Weighted Average Shares Outstanding: | |||||||||
Basic | 20,973 | 20,644 | |||||||
Diluted | 20,973 | 21,633 | |||||||
In periods with a net loss, the basic loss per share equals the diluted
loss per share as all common stock equivalents are excluded from the per
share calculation because they are anti-dilutive.
CONSOLIDATED BALANCE SHEET |
|||||||||
March 31 | December 31 | ||||||||
2019 | 2018 | ||||||||
(Unaudited) | |||||||||
CURRENT ASSETS | |||||||||
Cash & Cash Equivalents | $ | 2,457 | $ | 5,015 | |||||
Accounts Receivable – net of reserves of $62 and $44, respectively | 12,129 | 8,638 | |||||||
Inventories – net of reserves of $1,830 and $1,910, respectively | 7,763 | 6,884 | |||||||
Prepaid Expenses and Other Current Assets | 1,017 | 1,689 | |||||||
TOTAL CURRENT ASSETS | 23,366 | 22,226 | |||||||
PROPERTY PLANT AND EQUIPMENT – NET | 2,517 | 2,578 | |||||||
OTHER ASSETS | |||||||||
Goodwill | 9,950 | 9,778 | |||||||
Acquired Intangible Assets, net | 3,001 | 3,206 | |||||||
Deferred Income Taxes | 5,751 | 5,592 | |||||||
Right Of Use Lease Asset | 1,766 | – | |||||||
Other Assets | 738 | 787 | |||||||
TOTAL OTHER ASSETS | 21,206 | 19,363 | |||||||
TOTAL ASSETS | $ | 47,089 | $ | 44,167 | |||||
CURRENT LIABILITIES | |||||||||
Short Term Debt | $ | 4,051 | $ | 2,016 | |||||
Accounts Payable | 5,215 | 3,252 | |||||||
Short Term Lease Liability | 423 | – | |||||||
Accrued Expenses and Other Current Liabilities | 2,967 | 6,083 | |||||||
Deferred Revenue | 207 | 103 | |||||||
TOTAL CURRENT LIABILITIES | 12,863 | 11,454 | |||||||
LONG TERM LIABILITIES | |||||||||
Long Term Lease Liability | 1,350 | – | |||||||
Other Long Term Liabilities | 96 | 115 | |||||||
Deferred Tax Liability | 628 | 616 | |||||||
TOTAL LONG TERM LIABILITIES | 2,074 | 731 | |||||||
COMMITMENTS AND CONTINGENCIES | |||||||||
SHAREHOLDERS’ EQUITY | |||||||||
Preferred Stock, $.01 par value, 2,000,000 shares authorized, none issued |
– | – | |||||||
Common Stock, $.01 par value, 75,000,000 shares authorized, 34,488,852 and 34,393,252 |
|||||||||
shares issued, 21,300,252 and 21,205,251 shares outstanding | 345 | 344 | |||||||
Additional Paid in Capital | 48,687 | 48,479 | |||||||
Retained Earnings | 7,212 | 7,556 | |||||||
Treasury Stock at Cost, 13,188,601 and 13,188,601 shares, respectively |
(24,509 | ) | (24,509 | ) | |||||
Accumulated Other Comprehensive Income | 417 | 112 | |||||||
TOTAL SHAREHOLDERS’ EQUITY | 32,152 | 31,982 | |||||||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 47,089 | $ | 44,167 | |||||
CONSOLIDATED STATEMENT OF CASH FLOWS |
|||||||||
For the Three Months | |||||||||
Ended March 31 | |||||||||
2019 | 2018 | ||||||||
CASH FLOWS USED BY OPERATING ACTIVITIES | |||||||||
Net Income/(Loss) | $ | (344 | ) | $ | 374 | ||||
Adjustments to reconcile net income/(loss) to net cash used by operating activities: |
|||||||||
Depreciation and Amortization | 549 | 626 | |||||||
Amortization of Debt Issuance Fees | 16 | 19 | |||||||
Share-based Compensation Expense | 209 | 188 | |||||||
Deferred Rent | (6 | ) | 5 | ||||||
Deferred Income Taxes | (159 | ) | 37 | ||||||
Provision for Doubtful Accounts | 18 | (1 | ) | ||||||
Inventory Reserves | 47 | 19 | |||||||
Changes in Assets and Liabilities, Net of Acquisition: | |||||||||
Accounts Receivable | (3,456 | ) | (1,574 | ) | |||||
Inventories | (916 | ) | (524 | ) | |||||
Prepaid Expenses and Other Assets | 792 | (507 | ) | ||||||
Accounts Payable | 1,888 | (255 | ) | ||||||
Payment of Contingent Consideration | (772 | ) | – | ||||||
Accrued Expenses and Other Liabilities | (1,235 | ) | 635 | ||||||
Net Cash Used by Operating Activities | (3,369 | ) | (958 | ) | |||||
CASH FLOWS USED BY INVESTING ACTIVITIES | |||||||||
Capital Expenditures | (128 | ) | (199 | ) | |||||
Acquisition of Business, Net of Cash Acquired | (426 | ) | (811 | ) | |||||
Net Cash Used by Investing Activities | (554 | ) | (1,010 | ) | |||||
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES | |||||||||
Revolver Borrowings | 9,788 | 10,603 | |||||||
Revolver Repayments | (7,715 | ) | (9,191 | ) | |||||
Term Loan Repayments | (38 | ) | (38 | ) | |||||
Payment of Contingent Consideration | (782 | ) | – | ||||||
Proceeds from Exercise of Stock Options | – | 288 | |||||||
Net Cash Provided by Financing Activities | 1,253 | 1,662 | |||||||
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 112 | 88 | |||||||
NET DECREASE IN CASH AND CASH EQUIVALENTS | (2,558 | ) | (218 | ) | |||||
Cash and Cash Equivalents, at Beginning of Period | 5,015 | 2,458 | |||||||
CASH AND CASH EQUIVALENTS, AT END OF PERIOD | $ | 2,457 | $ | 2,240 | |||||
SUPPLEMENTAL INFORMATION: | |||||||||
Cash Paid During the Period for Interest | $ | 41 | $ | 36 | |||||
Cash Paid During the Period for Income Taxes | $ | 26 | $ | 9 | |||||
NET REVENUE AND GROSS PROFIT BY SEGMENT |
||||||||||||||||||||
Three months ended March 31 | ||||||||||||||||||||
Revenue | % of Revenue | Change | ||||||||||||||||||
2019 | 2018 | 2019 | 2018 | Amount | Pct. | |||||||||||||||
Network Solutions | $ | 5,758 | $ | 5,511 | 44.2 | % | 41.5 | % | $ | 247 | 4.5 | % | ||||||||
Test and Measurement | 3,030 | 3,763 | 23.3 | % | 28.4 | % | (733 | ) | -19.5 | % | ||||||||||
Embedded Solutions | 4,244 | 3,990 | 32.6 | % | 30.1 | % | 254 | 6.4 | % | |||||||||||
Total Net Revenues | $ | 13,032 | $ | 13,264 | 100.0 | % | 100.0 | % | $ | (232 | ) | -1.7 | % | |||||||
Three months ended March 31 | ||||||||||||||||||||
Gross Profit | Gross Profit % | Change | ||||||||||||||||||
2019 | 2018 | 2019 | 2018 | Amount | Pct. | |||||||||||||||
Network Solutions | $ | 2,389 | $ | 2,442 | 41.5 | % | 44.3 | % | $ | (53 | ) | -2.2 | % | |||||||
Test and Measurement | 1,569 | 1,845 | 51.8 | % | 49.0 | % | (276 | ) | -15.0 | % | ||||||||||
Embedded Solutions | 1,769 | 1,981 | 41.7 | % | 49.6 | % | (212 | ) | -10.7 | % | ||||||||||
Total Gross Profit | $ | 5,727 | $ | 6,268 | 43.9 | % | 47.3 | % | $ | (541 | ) | -8.6 | % | |||||||
RECONCILIATION OF NET INCOME TO NON-GAAP EBITDA AND NON-GAAP |
|||||||||
Three Months Ended | |||||||||
March 31 | |||||||||
2019 |
2018 |
||||||||
GAAP Net Income/(Loss), as reported | $ | (344 | ) | $ | 374 | ||||
Tax Provision/(Benefit) | (138 | ) | 56 | ||||||
Depreciation and Amortization Expense | 549 | 626 | |||||||
Interest Expense | 115 | 92 | |||||||
Non-GAAP EBITDA | 182 | 1,148 | |||||||
Stock Compensation Expense | 209 | 188 | |||||||
ASC 606 Adjustment | – | 188 | |||||||
Integration Expenses | – | 48 | |||||||
Inventory Recovery | (2 | ) | (8 | ) | |||||
FX (Gain)/Loss | (35 | ) | 48 | ||||||
Non-GAAP Adjusted EBITDA | $ | 354 | $ | 1,612 | |||||
Contacts
Mike Kandell
(973) 386-9696
Or
John Nesbett
or Jen Belodeau
(203) 972 9200
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Medical Cannabis Market Report 2024-2030: Asia-Pacific Set to Witness Robust Growth, Driven by R&D Discovery Initiatives
Cannabis
Rubicon Organics Reports Q1 2024 Financial Results
SCHWAZZE
Schwazze Announces First Quarter 2024 Financial Results
Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time
DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.
“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”
“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”
“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”
“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”
First Quarter 2024 Financial Summary
$ in Thousands USD |
Q1 2024 |
Q4 2023 |
Q1 2023 |
Total Revenue |
$41,601 |
$43,325 |
$40,001 |
Gross Profit |
$17,934 |
$7,034[1] |
$21,849 |
Operating Expenses |
$20,643 |
$23,276 |
$16,199 |
Income (Loss) from Operations |
$(2,709) |
$(16,242) |
$5,650 |
Adjusted EBITDA[2] |
$7,341 |
$10,953 |
$14,525 |
Operating Cash Flow |
$(3,700) |
$3,452 |
$(880) |
Recent Highlights
- Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
- Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
- Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
- Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.
First Quarter 2024 Financial Results
Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.
Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.
____________________________ |
1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. |
Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.
Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.
Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.
As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.
Conference Call
The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.
Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].
Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call
The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.
Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910
If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.
About Schwazze
Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.
Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.
Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.
Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars
March 31, |
December 31, |
||||
2024 |
2023 |
||||
ASSETS
|
|||||
Current Assets |
|||||
Cash & Cash Equivalents |
$ |
13,151,317 |
$ |
19,248,932 |
|
Accounts Receivable, net of Allowance for Doubtful Accounts |
3,356,032 |
4,261,159 |
|||
Inventory |
26,382,184 |
25,787,793 |
|||
Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively |
108,583 |
456,099 |
|||
Prepaid Expenses & Other Current Assets |
3,502,310 |
3,914,064 |
|||
Total Current Assets |
46,500,426 |
53,668,047 |
|||
Non-Current Assets |
|||||
Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively |
31,326,000 |
31,113,630 |
|||
Investments |
2,000,000 |
2,000,000 |
|||
Investments Held for Sale |
– |
202,111 |
|||
Goodwill |
67,492,705 |
67,499,199 |
|||
Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively |
162,391,482 |
166,167,877 |
|||
Other Non-Current Assets |
1,328,187 |
1,263,837 |
|||
Operating Lease Right of Use Assets |
34,575,832 |
34,233,142 |
|||
Deferred Tax Assets, net |
992,144 |
1,996,489 |
|||
Total Non-Current Assets |
300,106,350 |
304,476,285 |
|||
Total Assets |
$ |
346,606,776 |
$ |
358,144,332 |
|
LIABILITIES & STOCKHOLDERS’ EQUITY
|
|||||
Current Liabilities |
|||||
Accounts Payable |
$ |
9,443,233 |
$ |
13,341,561 |
|
Accrued Expenses |
8,106,618 |
7,774,691 |
|||
Derivative Liabilities |
1,319,845 |
638,020 |
|||
Lease Liabilities – Current |
5,186,316 |
4,922,724 |
|||
Current Portion of Long Term Debt |
29,579,713 |
3,547,011 |
|||
Income Taxes Payable |
28,235,039 |
25,232,782 |
|||
Total Current Liabilities |
81,870,764 |
55,456,789 |
|||
Non-Current Liabilities |
|||||
Long Term Debt, net of Debt Discount & Issuance Costs |
130,120,753 |
153,262,203 |
|||
Lease Liabilities – Non-Current |
30,735,072 |
30,133,452 |
|||
Total Non-Current Liabilities |
160,855,825 |
183,395,655 |
|||
Total Liabilities |
$ |
242,726,589 |
$ |
238,852,444 |
|
Stockholders’ Equity |
|||||
Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and |
|||||
82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of |
|||||
December 31, 2023. |
82 |
86 |
|||
Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued |
|||||
and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued |
|||||
and 73,968,242 Shares Outstanding as of December 31, 2023. |
79,169 |
74,888 |
|||
Additional Paid-In Capital |
202,677,665 |
202,040,968 |
|||
Accumulated Deficit |
(96,843,602) |
(80,790,927) |
|||
Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and |
|||||
920,150 Shares Held as of December 31, 2023. |
(2,033,127) |
(2,033,127) |
|||
Total Stockholders’ Equity |
103,880,187 |
119,291,888 |
|||
Total Liabilities & Stockholders’ Equity |
$ |
346,606,776 |
$ |
358,144,332 |
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars
For the Three Months Ended |
|||||
March 31, |
|||||
2024 |
2023 |
||||
(Unaudited) |
(Unaudited) |
||||
Operating Revenues |
|||||
Retail |
$ |
37,633,252 |
$ |
35,820,111 |
|
Wholesale |
3,898,320 |
4,058,925 |
|||
Other |
69,421 |
121,900 |
|||
Total Revenue |
41,600,993 |
40,000,936 |
|||
Total Cost of Goods & Services |
23,667,319 |
18,152,163 |
|||
Gross Profit |
17,933,674 |
21,848,773 |
|||
Operating Expenses |
|||||
Selling, General and Administrative Expenses |
11,835,818 |
10,100,934 |
|||
Professional Services |
1,671,881 |
1,187,364 |
|||
Salaries |
6,880,988 |
4,695,971 |
|||
Stock Based Compensation |
253,916 |
214,544 |
|||
Total Operating Expenses |
20,642,603 |
16,198,813 |
|||
Income from Operations |
(2,708,929) |
5,649,960 |
|||
Other Income (Expense) |
|||||
Interest Expense, net |
(8,307,369) |
(7,745,854) |
|||
Unrealized Gain (Loss) on Derivative Liabilities |
(681,825) |
8,501,685 |
|||
Other Loss |
10,500 |
– |
|||
Loss on Investment |
(33,382) |
– |
|||
Unrealized Gain on Investment |
(347,516) |
1,816 |
|||
Total Other Income (Expense) |
(9,359,592) |
757,647 |
|||
Pre-Tax Net Income (Loss) |
(12,068,521) |
6,407,607 |
|||
Provision for Income Taxes |
3,984,154 |
4,662,178 |
|||
Net Income (Loss) |
$ |
(16,052,675) |
$ |
1,745,429 |
|
Less: Accumulated Preferred Stock Dividends for the Period |
(2,155,259) |
(2,029,394) |
|||
Net Income (Loss) Attributable to Common Stockholders |
$ |
(18,207,934) |
$ |
(283,965) |
|
Earnings (Loss) per Share Attributable to Common Stockholders |
|||||
Basic Earnings (Loss) per Share |
$ |
(0.24) |
$ |
(0.01) |
|
Diluted Earnings (Loss) per Share |
$ |
(0.24) |
$ |
(0.06) |
|
Weighted Average Number of Shares Outstanding – Basic |
76,006,932 |
55,835,501 |
|||
Weighted Average Number of Shares Outstanding – Diluted |
76,006,932 |
101,608,278 |
|||
Comprehensive Income (Loss) |
$ |
(16,052,675) |
$ |
1,745,429 |
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars
For the Three Months Ended |
|||||
March 31, |
|||||
2024 |
2023 |
||||
(Unaudited) |
(Unaudited) |
||||
Cash Flows from Operating Activities: |
|||||
Net Income (Loss) for the Period |
$ |
(16,052,675) |
$ |
1,745,429 |
|
Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities |
|||||
Depreciation & Amortization |
5,096,314 |
6,151,395 |
|||
Non-Cash Interest Expense |
1,031,431 |
991,184 |
|||
Non-Cash Lease Expense |
2,871,226 |
2,251,459 |
|||
Deferred Taxes |
1,004,345 |
(637,225) |
|||
Loss on Investment |
202,111 |
– |
|||
Change in Derivative Liabilities |
681,825 |
(8,501,685) |
|||
Amortization of Debt Issuance Costs |
421,512 |
421,513 |
|||
Amortization of Debt Discount |
2,303,246 |
1,999,933 |
|||
(Gain) Loss on Investments, net |
347,516 |
(1,816) |
|||
Stock Based Compensation |
640,974 |
214,544 |
|||
Changes in Operating Assets & Liabilities (net of Acquired Amounts): |
|||||
Accounts Receivable |
905,127 |
(118,181) |
|||
Inventory |
(587,900) |
(3,023,251) |
|||
Prepaid Expenses & Other Current Assets |
411,754 |
(3,036,801) |
|||
Other Assets |
(64,350) |
360,674 |
|||
Change in Operating Lease Liabilities |
(2,348,703) |
(1,531,765) |
|||
Accounts Payable & Other Liabilities |
(3,566,401) |
(3,464,671) |
|||
Income Taxes Payable |
3,002,257 |
5,299,403 |
|||
Net Cash Provided by (Used in) Operating Activities |
(3,700,390) |
(879,861) |
|||
Cash Flows from Investing Activities: |
|||||
Collection of Notes Receivable |
– |
10,631 |
|||
Purchase of Fixed Assets |
(1,532,287) |
(2,913,394) |
|||
Net Cash Provided by (Used in) Investing Activities |
(1,532,287) |
(2,902,763) |
|||
Cash Flows from Financing Activities: |
|||||
Payment on Notes Payable |
(864,938) |
– |
|||
Net Cash Provided by (Used in) Financing Activities |
(864,938) |
– |
|||
Net (Decrease) in Cash & Cash Equivalents |
(6,097,615) |
(3,782,624) |
|||
Cash & Cash Equivalents at Beginning of Period |
19,248,932 |
38,949,253 |
|||
Cash & Cash Equivalents at End of Period |
$ |
13,151,317 |
$ |
35,166,628 |
|
Supplemental Disclosure of Cash Flow Information: |
|||||
Cash Paid for Interest |
$ |
4,515,205 |
$ |
6,540,748 |
MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars
For the Three Months Ended |
|||||
March 31, |
|||||
2024 |
2023 |
||||
Net Income (Loss) |
$ |
(16,052,675) |
$ |
1,745,429 |
|
Interest Expense, net |
8,307,369 |
7,745,854 |
|||
Provision for Income Taxes |
3,984,154 |
4,662,178 |
|||
Other (Income) Expense, net of Interest Expense |
1,052,223 |
(8,503,501) |
|||
Depreciation & Amortization |
5,618,834 |
6,612,814 |
|||
Earnings Before Interest, Taxes, Depreciation and |
|||||
Amortization (EBITDA) (non-GAAP) |
$ |
2,909,905 |
$ |
12,262,774 |
|
Non-Cash Stock Compensation |
253,916 |
214,544 |
|||
Deal Related Expenses |
637,761 |
1,195,802 |
|||
Capital Raise Related Expenses |
20,760 |
35,068 |
|||
Severance |
484,561 |
118,436 |
|||
Retention Program Expenses |
807,500 |
280,632 |
|||
Pre-Operating & Dark Carry Expenses |
1,053,837 |
391,917 |
|||
One-Time Legal Settlements |
417,653 |
– |
|||
Other Non-Recurring Items |
754,751 |
25,707 |
|||
Adjusted EBITDA (non-GAAP) |
$ |
7,340,644 |
$ |
14,524,880 |
|
Revenue |
41,600,993 |
40,000,936 |
|||
Adjusted EBITDA Percent |
17.6 % |
36.3 % |
View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html
-
Cannabis1 week ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis2 weeks ago
IM Cannabis Reports First Quarter Financial Results
-
Innocan1 week ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis6 days ago
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
-
Cannabis6 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis4 days ago
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032
-
SCHWAZZE4 days ago
Schwazze Announces First Quarter 2024 Financial Results
-
Cannabis5 days ago
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth